The rooftops in the photo above belong to the old medina of Sfax, Tunisia. In 2011, doctors there linked generalized pustular psoriasis (GPP) in 9 families to a single gene. That discovery pointed to the IL-36 pathway, which Spevigo, the first drug the FDA approved for GPP, now blocks. The same pathway is the target of imsidolimab, a second drug the FDA is due to decide on by December 12, 2026.
For anyone living with GPP, that decision could mean a second choice for treating flares and keeping them away. Vanda Pharmaceuticals plans to sell imsidolimab as Quimilza, and it blocks the same signal in the skin that Spevigo blocks.
Both companies report results near 53%, and the 2 figures are easy to set side by side. They were measured on different days with different yardsticks, though, so this post lines up where each trial drew its finish line.
What Is Imsidolimab (Quimilza), and When Will the FDA Decide on It?
Imsidolimab is an investigational antibody for generalized pustular psoriasis that blocks the interleukin-36 (IL-36) receptor, and the FDA's goal date for deciding on it is December 12, 2026. Vanda announced on February 25, 2026 that the FDA had accepted its application for review.
Vanda's October 2026 quarterly report uses the planned brand name Quimilza, which becomes official only if the FDA approves the drug. Vanda licensed worldwide rights in February 2025 from AnaptysBio, the company that ran the 2 main trials.
The first of those trials, GEMINI-1, gave 45 adults in the middle of a flare a single infusion of imsidolimab at 300mg or 750mg, or a placebo. GEMINI-2 then followed people who responded on monthly 200mg injections under the skin (Smieszek et al., 2026).
Vanda's chief executive, Mihael Polymeropoulos, called the drug "a precision medicine approach targeting a disorder with a known genetic cause" when the application was accepted. That genetic cause is where the story of both GPP drugs begins.
A Gene Found in 9 Tunisian Families Pointed to Both GPP Drugs' Target
In August 2011, a team whose first author was a Hedi Chaker Hospital dermatologist reported the cause of GPP in 9 Tunisian families, each with several affected members. Their New England Journal of Medicine paper opened by calling GPP "a life-threatening disease of unknown cause" (Marrakchi et al., 2011).
Every sick family member carried 2 changed copies of a gene called IL36RN. That gene makes IL-36Ra, a natural brake on the IL-36 signal in skin, and the changed brake worked poorly. Without it, skin cells pour out signals that call in neutrophils, the white blood cells that fill a pustule. Those neutrophils switch on still more IL-36 (Johnston et al., 2017).
A London team found the same gene on its own that month, in 5 unrelated patients. It pointed to IL-1 family signaling, which includes IL-36, as a potential target for treatment (Onoufriadis et al., 2011). The condition came to be called DITRA, short for deficiency of the IL-36 receptor antagonist.
Many people with GPP do not carry the gene change. In a Japanese study, 9 of 11 people with GPP alone had 2 changed copies, against 2 of 20 people who also had ordinary plaque psoriasis (Sugiura et al., 2013). Both drugs block the IL-36 receptor itself, past the point where the brake fails, and Spevigo's label does not require a genetic test.
The thread from Sfax runs right through the trials. Two of the Sfax dermatologists on the 2011 gene paper are also authors of the 2021 Spevigo trial paper (Bachelez et al., 2021). Vanda lists Tunisia among the 11 countries where the imsidolimab trials ran, and a dermatologist from Sousse, Tunisia, is an author of their published results.
What a Generalized Pustular Psoriasis Flare Does to the Body
A GPP flare can arrive with fever, chills, intense itching, a racing pulse and exhaustion, according to the National Psoriasis Foundation. It can also bring a sudden drop in blood pressure. Infections, stress, pregnancy and stopping corticosteroid treatment are the most common triggers the foundation lists.
“The pain feels like a paper cut multiplied by 10,000”
Dale Reisner, who has had GPP since 2005, in a 2023 journal interview sponsored by Boehringer Ingelheim
Reisner described a household rebuilt around flares, down to replacing every doorknob with a lever handle, in that interview published in Clinical, Cosmetic and Investigational Dermatology. Boehringer Ingelheim made Spevigo at the time, so the interview reflects a patient voice the drugmaker helped bring forward.
Hospital records show how serious a flare can be. At 20 US academic centers, 36.8% of 95 adults with GPP were admitted to hospital at their first visit (Noe et al., 2022). In England, a 2026 study of 991 people with GPP found more than 3 times the risk of death of people without it. The risk of death from sepsis, a body-wide reaction to infection, was more than 9 times higher (British Journal of Dermatology, 2026).
Loneliness runs through the disease as well. Leah Howard, president and CEO of the National Psoriasis Foundation, has said that people with this rare form of psoriasis "feel very alone" with it. The foundation noted that many have never met another person with GPP when it announced a 2025 awareness campaign sponsored by Boehringer Ingelheim.
Spevigo's 54% and Imsidolimab's 53% Were Measured on Different Days
Spevigo's 54% and imsidolimab's 53% are different kinds of number. Spevigo's is the share of people with no visible pustules 1 week after a single infusion, and imsidolimab's is the share rated clear or almost clear 4 weeks after one.
Doctors in both trials scored skin on a 0 to 4 scale called the GPP Physician Global Assessment, where 0 means clear and 1 almost clear. Spevigo's main goal looked only at the pustule part of that score and asked for a 0, meaning no visible pustules. In that trial, more people reached a pustule score of 0 (54%) than a whole score of 0 or 1 (43%) (Bachelez et al., 2021).
Spevigo was judged at week 1 and imsidolimab at week 4, on different yardsticks, so the 2 drugs never crossed the same finish line. On the shared clear-or-almost-clear score, Spevigo reached 43% against 11% on placebo at week 1, and imsidolimab 53% against 13% at week 4. Imsidolimab's prevention result comes from 8 people per group who had responded in GEMINI-1, and its follow-on trial's main goal was safety. The 2 prevention trials also defined a flare differently, and in both flare trials placebo patients who were not improving could switch to the study drug after day 8.
Trial Friend built this chart on November 17, 2026 from 6 sources. Those were the Spevigo label, the 2 Spevigo trial papers, LEO Pharma's results page, the GEMINI-1 paper in NEJM Evidence and the GEMINI-2 ClinicalTrials.gov record. Each pair of dots comes from 1 randomized comparison, so no drug is set against another trial's placebo group.
Spevigo (Spesolimab), Approved Since 2022 and Now Sold by LEO Pharma
The FDA approved Spevigo on September 1, 2022 as an infusion for GPP flares in adults. On March 18, 2024 it widened the approval to GPP in people 12 and older who weigh at least 40kg and added a shot under the skin to prevent flares. LEO Pharma took over Spevigo from Boehringer Ingelheim on October 1, 2025.
For a flare, the label calls for one 900mg infusion over 90 minutes, with a second allowed a week later if symptoms persist. To prevent flares, people get a 600mg starting dose under the skin, then 300mg every 4 weeks. If their doctor decides it is appropriate, patients 12 and older or a caregiver can give the shots after training.
That 54% comes with a short window. On day 8 of the Spevigo flare trial, 83% of the placebo group received Spevigo openly. For that reason the trial paper says the comparison with placebo could not be determined after week 1 (Bachelez et al., 2021).
The prevention trial enrolled people with at least 2 earlier moderate-to-severe flares. By week 48, 10% on the approved dose (3 of 30) had a flare, against 52% on placebo (16 of 31). Those figures come from the label and the Lancet paper (Morita et al., 2023). Mark Lebwohl, the flare trial's lead investigator, called the 2022 approval "a turning point for dermatologists and clinicians," Fierce Pharma reported.
Spevigo has no boxed warning. Its label warns about infections, which affected 14% on Spevigo and 6% on placebo in the first week. It also warns about serious allergic reactions, including a severe skin and organ reaction called DRESS. Spevigo is not for anyone who has had a severe allergic reaction to it. The label requires a tuberculosis check before the first dose and says to avoid live vaccines during treatment and for at least 16 weeks after.
Imsidolimab (Quimilza), Decision Due December 12th
In GEMINI-1, 8 of 15 people on each dose of imsidolimab (53%) were clear or almost clear at week 4, against 2 of 15 on placebo (13%). By week 1, pustules were clear or almost clear in 67% on 300mg and 40% on 750mg, against 13% on placebo, according to the trial's registry record.
Placebo patients who were not improving after day 8 could leave GEMINI-1 early and become eligible for rescue imsidolimab, and 10 of the 15 did, according to AnaptysBio. Only 5 people on placebo completed the trial, which its ClinicalTrials.gov record shows.
GEMINI-2 tested whether monthly shots kept the response going. In GEMINI-2, 16 people who responded in GEMINI-1 were randomly assigned to imsidolimab or placebo, 8 in each group. All 8 on imsidolimab stayed clear or almost clear with no flare, AnaptysBio reported. Of the 8 on placebo, 63% had a flare during 24 to 92 weeks of follow-up. The chart instead uses the registry's week-24 count, which has 63% of the placebo group still free of flares. The registry lists GEMINI-2 as terminated, explaining that AnaptysBio concluded it after all participants had about 6 months of imsidolimab and the longest-treated reached 104 weeks.
No serious adverse events led anyone to stop imsidolimab in GEMINI-2, the published paper says, and nobody on imsidolimab in GEMINI-1 had a serious adverse event, according to the registry. The GEMINI-2 registry results list serious adverse events in 4 of the 29 people given imsidolimab there, none of them among the 8 randomized to it. Vanda describes the safety profile as favorable, and the label the FDA writes will set the warnings that apply.
Getting a Head Start Before the December 12th Imsidolimab Decision
Nobody can start imsidolimab before the FDA acts, but some groundwork takes weeks and would help with either IL-36 drug. These steps are ones a person with GPP can take with their own care team now.
- Write down your flare history, including dates, suspected triggers, hospital stays and each treatment tried with how it went. Spevigo's prevention trial enrolled only people with at least 2 earlier moderate-to-severe flares, and a dated record makes that history easy to show.
- Ask your dermatologist whether imsidolimab could suit you if approved, and how they would choose between it and Spevigo. The imsidolimab trials enrolled adults aged 18 to 80, while Spevigo's label starts at age 12 and 40kg.
- Ask whether a tuberculosis test and a vaccine review make sense now. Spevigo's label calls for both before the first dose, and imsidolimab's label is not public, so whether it will ask the same is not yet known.
- Call the pharmacy number on your insurance card and ask how the plan reviews newly approved specialty drugs, and whether Spevigo is covered today.
- Sign up below for 1 email on the day the FDA acts, and check the imsidolimab FDA calendar page for the live status.
One email when the decision is public, with what it means in plain language, plus new trials and FDA news for Generalized Pustular Psoriasis. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
No GPP drug trial was recruiting at a US site on ClinicalTrials.gov when Trial Friend checked on November 17, 2026. The only GPP drug trial listed as recruiting, of a drug called HB0034, lists 2 sites in China. Its record was last verified in March 2025, and the GPP page tracks new studies as they open.
In the 15 years since the Sfax paper, the signal that a missing brake leaves unchecked has become the target of 1 approved medicine. A second awaits its FDA decision on December 12th.
Imsidolimab, Spevigo and GPP, Answered Briefly
Is imsidolimab FDA approved?
Imsidolimab was not FDA approved as of November 17, 2026, and the FDA's goal date for a decision is December 12, 2026. Vanda Pharmaceuticals submitted the application in December 2025, and the FDA accepted it in February 2026.
What is Quimilza?
Quimilza is the brand name Vanda Pharmaceuticals plans to use for imsidolimab, its IL-36 receptor antibody for generalized pustular psoriasis. The name becomes official only if the FDA approves the drug.
Is imsidolimab better than Spevigo?
No trial has compared imsidolimab with Spevigo directly, so neither can be called better. Their trials measured success on different days with different yardsticks, and a dermatologist weighs a person's history, age and flare pattern when choosing between treatments.
Who makes Spevigo now?
LEO Pharma took over Spevigo on October 1, 2025, when it closed its deal with Boehringer Ingelheim. The current label, the SPEVIGO Patient Support Program and the side effect reporting line are LEO's.
Can teenagers get Spevigo for GPP?
Spevigo is approved for children 12 and older who weigh at least 40kg, for both flares and prevention. Its safety and effectiveness have not been established in children under 12 or under 40kg, according to the label.
What was GPP in pregnancy called?
GPP flares during pregnancy were once called impetigo herpetiformis, and they usually occur in the third trimester, according to the National Psoriasis Foundation. Pregnancy is one of the triggers the foundation lists for GPP flares.
